Answers are grounded in this paper and cite their sources.
Phosphodiesterase type 5 (PDE5) hydrolyses cyclic guanylate monophosphate specifically to 5′ guanylate monophosphate, promoting corporeal vascular relaxation and penile erection in response to sexual stimulation. Oral PDE5 inhibitors (PDE5-Is) have afforded effective and well-tolerated treatment for erectile dysfunction. In addition, PDE5-Is have stimulated academic and clinical interest for their potential benefits in diverse non-sexual applications. To highlight possible potential non-sexual implications of PDE5-Is. A systematic review was conducted until January 2016 based on a search of all relevant articles in Medline Medical Subject Heading, Scopus, Cochrane Library, EMBASE, and CINAHL databases without language restriction. Key words used to assess outcome and estimates for the relevant associations were PDE5 inhibitors, sildenafil, tadalafil , vardenafil , and avanafil. Different non-sexual implications for PDE5-Is. PDE5-Is demonstrated beneficial effects in different medical applications with possible widespread implications for cardiovascular, pulmonary, cutaneous, gastrointestinal, urogenital, cellular, musculoskeletal, neurologic, and reproductive disorders. However, most applications were carried out experimentally in preclinical studies of off-label indications. PDE5-Is are a conceptually attractive therapeutic class of agents with pleiotropic effects. Exploring PDE5-Is for their possible implications seems to be valuable in different medical disorders. However, well-designed clinical trials are needed before these agents can be recommended for selected applications. Mostafa T. Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. Sex Med Rev 2017;5:170–199.
No takes yet. Share an insight, caveat, or question.
Taymour Mostafa (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: